TrialInvestigational new drugs2006

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.

Sanjay Goel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.